The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes: Testing the Moderating Effects of Socioeconomic and Cultural Factors
Status: Recruiting
Location: See location...
Intervention Type: Other, Behavioral, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study will discuss the impact of continuous glucose monitoring on maternal and infant's outcomes in gestational diabetes mellitus, and test the moderating effect of socioeconomic and cultural factors (dietary habits, socioeconomic status and income).
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Aged 18 years or above
• Pregnant women diagnosed with gestational diabetes mellitus
• Those who are willing to participate in this study
Locations
Other Locations
Taiwan
National Taiwan University Hospital Hsin-Chu Branch BioMedical Park Hospital
RECRUITING
Hsinchu
Contact Information
Primary
HUNG-HUI CHEN, PhD
hunghuichen@ntu.edu.tw
886-2-2394-7109
Time Frame
Start Date: 2024-08-22
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 120
Treatments
Other: Controlled group-Blood glucose meters (BGM) group
The participants will receive structured questionnaires and blood tests (glycated albumin, fasting plasma glucose, insulin, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein) at 24-32 weeks of pregnancy, 35 weeks of pregnancy to before delivery, and 4-12 weeks postpartum, respectively.~Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 14 days of glucose monitoring at 24-32 weeks of pregnancy, a glucose monitor report will be given to the participants. After the 14 days of glucose monitoring at 33 weeks to before delivery , another glucose monitor report will be given to the participants.
Experimental: Experimental group1-Continuous glucose monitoring (CGM) group
The participants will receive structured questionnaires and blood tests (glycated albumin, fasting plasma glucose, insulin, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein) at 24-32 weeks of pregnancy, 35 weeks of pregnancy to before delivery, and 4-12 weeks postpartum, respectively.~Participants will receive a set of continuous glucose monitor (CGM) respectively at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set).
Experimental: Experimental group2-Continuous glucose monitoring (CGM) with nursing care group
The participants will receive structured questionnaires and blood tests (glycated albumin, fasting plasma glucose, insulin, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein) at 24-32 weeks of pregnancy, 35 weeks of pregnancy to before delivery, and 4-12 weeks postpartum, respectively.~Participants will receive a set of continuous glucose monitor (CGM) respectively at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set).~Participants will receive perinatal nursing care for gestational diabetes.
Related Therapeutic Areas
Sponsors
Leads: National Taiwan University Hospital